MabThera 100 mg concentrate for solution for infusion clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
This study is testing a new type of cell therapy called KYV101 for people with serious forms of multiple sclerosis (MS) that are getting worse. It compares this new treatment with existing MS medications to see how well it works and if it's safe.
For: Primary or Secondary Progressive Multiple SclerosisGermany · Italy · Belgium - AuthorisedTherapeutic exploratory (Phase II)
Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma
This study looks at new ways to treat a rare type of brain lymphoma in adults. It combines chemotherapy with newer immune-boosting drugs. Doctors want to see if this treatment helps patients live longer, whether they are newly diagnosed or if their cancer has returned.
For: Primaari aivolymfomaa · ensilinjan hoito tai hoito relapoituneessa tai refraktaarissa taudissaFinland - AuthorisedTherapeutic confirmatory (Phase III)
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2
This study compares new drug combinations (pirtobrutinib and epcoritamab) with standard treatment for a type of lymphoma called Richter Transformation. It aims to see if the new treatments stop the cancer from growing for longer. Participants will get either the new drugs or standard chemotherapy.
For: previously untreated RT · irrespective of risk factors and disease stageAustria · Germany · Denmark